Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Testing the metabotropic glutamate receptor theory in fragile X syndrome: a randomized, placebo-controlled, proof-of-concept study of AFQ056, a novel, sub-type selective mGluR5 inhibitor

Testing the metabotropic glutamate receptor theory in fragile X syndrome: a randomized, placebo-controlled, proof-of-concept study of AFQ056, a novel, sub-type selective mGluR5 inhibitor. American Society of Human Genetics 2010. 2010.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.